Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.

Trial Details

NCT ID
NCT06353997
Phase
PHASE2
Sponsor
Providence Health & Services
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Pembrolizumab
  • INBRX-106
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Portland, Oregon, United States|45.52345,-122.67621
  • Portland, Oregon, United States|45.52345,-122.67621
  • Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

  • Age ≥ 18 years, inclusive of all genders.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 2.
  • Patients must have histologically confirmed TNBC (ER/PR ≤ 10% allowed, HER2- as defined by ASCO guidelines). HER2 negative permitted to enroll as I…
  • Primary breast tumor measurable by ultrasound and at least 1cm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →